CTE peaked at 46c on January 13 but then sagged under selling pressure applied by Cell Care as it exited it's position as second ranking holder with ~19%.
The stock has been recovering over the last two months as institutions such as DMX Asset Management establish positions.
Today's heavy turnover signals more institutional interest.
And yes, @stocking, I agree that the SP "should be easily over 0.4". I'd go further. It should be easily over 50c.
At 50c the group would have an enterprise value of around $18.5m - a modest figure given its pivotal position in the burgeoning Australian clinical trials market.
CTE Price at posting:
32.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)